(Q33400780)

26 July 2017

title

Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management (English)

1 reference

26 July 2017

1

Morie A Gertz

1 reference

26 July 2017

publication date

1 May 2012

1 reference

American Journal of Hematology

26 July 2017

published in

1 reference

26 July 2017

volume

87

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

503-510

1 reference

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

26 July 2017

cites work

1 reference

Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: A two-institution study

21 January 2018

1 reference

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.

21 January 2018

1 reference

Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients

21 January 2018

1 reference

Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia

21 January 2018

1 reference

Neurological manifestations of Waldenström macroglobulinemia

21 January 2018

1 reference

Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia

21 January 2018

1 reference

Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.

21 January 2018

1 reference

IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia

21 January 2018

1 reference

Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study

21 January 2018

1 reference

How I treat Waldenström macroglobulinemia

21 January 2018

1 reference

Autoantibody activity in Waldenstrom's macroglobulinemia

21 January 2018

1 reference

Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.

21 January 2018

1 reference

Prevalence, clinical aspects, and natural history of IgM MGUS.

21 January 2018

1 reference

Pathogenesis and progression of monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia

21 January 2018

1 reference

Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification

21 January 2018

1 reference

Prognostic factors in follicular lymphoma.

21 January 2018

1 reference

International prognostic scoring system for Waldenstrom macroglobulinemia

21 January 2018

1 reference

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

21 January 2018

1 reference

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia

21 January 2018

1 reference

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

21 January 2018

1 reference

Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase

21 January 2018

1 reference

The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

21 January 2018

1 reference

21 January 2018

Hyperviscosity syndrome.

1 reference

Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome.

21 January 2018

1 reference

Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).

21 January 2018

1 reference

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

21 January 2018

1 reference

Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil

21 January 2018

1 reference

Monoclonal gammopathy and neuropathy.

21 January 2018

1 reference

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

21 January 2018

1 reference

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

21 January 2018

1 reference

Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003)

21 January 2018

1 reference

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

21 January 2018

1 reference

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Stu

21 January 2018

1 reference

Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.

21 January 2018

1 reference

Fludarabine-based combination therapies for Waldenström's macroglobulinemia.

21 January 2018

1 reference

21 January 2018

1 reference

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs

21 January 2018

1 reference

Current status of stem cell mobilization

21 January 2018

1 reference

High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 cases

21 January 2018

1 reference

Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique

21 January 2018

1 reference

Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia

21 January 2018

1 reference

Thalidomide and rituximab in Waldenstrom macroglobulinemia

21 January 2018

1 reference

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

21 January 2018

1 reference

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

21 January 2018

1 reference

Bortezomib in relapsed or refractory Waldenström's macroglobulinemia

21 January 2018

1 reference

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

21 January 2018

1 reference

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

21 January 2018

1 reference

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

21 January 2018

1 reference

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

21 January 2018

1 reference

Novel treatment regimens for Waldenström's macroglobulinemia

21 January 2018

1 reference

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

21 January 2018

1 reference

Waldenström's macroglobulinemia

21 January 2018

1 reference

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

21 January 2018

1 reference

Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia

21 January 2018

1 reference

Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23192

1 reference

26 July 2017

1 reference